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ABSTRACT ∃(∀
Context: The classic androgen synthesis pathway proceeds via DHEA, androstenedione and testosterone ∃)∀
to 5α-dihydrotestosterone (DHT). However, DHT synthesis can also be achieved by an alternative pathway ∃∗∀
originating from 17α-hydroxyprogesterone (17OHP), which accumulates in congenital adrenal hyperplasia %+∀
(CAH). Similarly, recent work has highlighted androstenedione-derived 11-oxygenated 19-carbon steroids %!∀
as active androgens and, in CAH, androstenedione is generated directly from 17OHP. The exact %#∀
contribution of alternative pathway activity to androgen excess in CAH and its response to glucocorticoid %∃∀
therapy is unknown.  %%∀
Objective: We sought to quantify classic and alternative pathway-mediated androgen synthesis in CAH, %&∀
their diurnal variation and their response to conventional glucocorticoid (GC) therapy and modified release %∋∀
hydrocortisone. %(∀
Methods: We employed urinary steroid metabolome profiling by gas chromatography-mass spectrometry %)∀
for 24-h steroid excretion analysis, studying the impact of conventional GCs (hydrocortisone, prednisolone, %∗∀
dexamethasone) in 55 adults with CAH and 60 controls. We studied diurnal variation in steroid excreton &+∀
by comparing 8-hourly collections (23:00-7:00h, 7:00-15:00h, 15:00-23:00h) in 16 CAH patients on &!∀
conventional glucocorticoids and during six months of treatment with modified release hydrocortisone, &#∀
Chronocort. &∃∀
Results: CAH patients on conventional GCs showed low excretion of classic pathway androgen metabolites &%∀
but excess excretion of the alternative pathway signature metabolites 3α,5α-17-hydroxypregnanolone and &&∀
11β-hydroxyandrosterone. Chronocort reduced 17OHP and alternative pathway metabolite excretion to &∋∀
near normal levels more consistently than other GC preparations.  &(∀
Conclusions: Alternative pathway mediated androgen synthesis significantly contributes to androgen &)∀
excess in CAH.  Chronocort therapy appears superior to conventional GC therapy in controlling androgen &∗∀
synthesis via alternative pathways through attenuation of their major substrate, 17OHP. ∋+∀
∋!∀
%∀
∀
INTRODUCTION ∋#∀
Disruption of glucocorticoid (GC) synthesis is the defining feature of all variants of congenital ∋∃∀
adrenal hyperplasia (CAH) including its most prevalent cause, 21-hydroxylase deficiency (21OHD) (1). ∋%∀
This enzymatic block results in GC deficiency, with the consequent loss of negative feedback to the ∋&∀
pituitary gland and hypothalamus, driving both ACTH-mediated adrenal androgen excess and adrenal ∋∋∀
hyperplasia. Mineralocorticoid deficiency may also be seen in 21OHD, but to a variable degree dependent ∋(∀
on mutation severity (2).  ∋)∀
The classic pathway of androgen synthesis proceeds through dehydroepiandrosterone (DHEA), ∋∗∀
androstenedione and testosterone to the most potent activator of the androgen receptor, 5α-(+∀
dihydrotestosterone (DHT). The substrate of 21-hydroxylase, 17α-hydroxyprogesterone (17OHP), (!∀
accumulates in CAH due to 21OHD, resulting in enhanced conversion to androstenedione and active (#∀
androgens. However, 17OHP is also a substrate for an alternative pathway to androgen biosynthesis, which (∃∀
generates DHT without the need for DHEA, androstenedione or testosterone as intermediates (3, 4). In this (%∀
pathway, 17OHP is converted by consecutive 5α-reductase and 3α-HSD activity to 3α,5α-17-(&∀
hydroxypregnanolone (3α,5α-17HP) and then downstream to DHT (Fig. 1) (5). Accumulation of the (∋∀
alternative pathway intermediate 3α,5α-17HP has been demonstrated in untreated patients with CAH due ((∀
to 21OHD (6), but its relative contribution to excess androgen synthesis has not yet been investigated. ()∀
Furthermore, recent work has highlighted the role of another androgen biosynthesis pathway that converts (∗∀
androstenedione in several steps to 11-keto-testosterone and 11-keto-dihydrotestosterone (Fig. 1), steroids )+∀
that have been shown to act as potent androgen receptor agonists (7-11). )!∀
Conventional management strategies for CAH include the use of both immediate release )#∀
hydrocortisone and longer-acting synthetic GC preparations, sometimes prescribed in a reverse circadian )∃∀
pattern (1). These preparations fail to mimic the normal diurnal profile of cortisol secretion and therefore )%∀
do not prevent the early morning surge of ACTH that is the major driver of adrenal-mediated androgen )&∀
excess in CAH. As a consequence, the current management of patients with CAH is complicated by the )∋∀
need to strike a balance between sufficient control of endogenous androgen excess and potential excess )(∀
&∀
∀
exposure to exogenous GCs (12). A modified and delayed release GC preparation, Chronocort, has recently ))∀
been developed and shown to approximate the physiological diurnal rhythm of cortisol release due to )∗∀
delayed release, with peak levels during the early morning hours after intake at bedtime (13, 14). The ∗+∀
relative impact of both conventional GC preparations and Chronocort on androgen synthesis by classic and ∗!∀
alternative pathways is not known.  ∗#∀
In this study, we sought to quantify the diurnal contribution of alternative pathway androgen ∗∃∀
synthesis to androgen excess in CAH by assessing the excreted urinary steroid metabolome of 21OHD ∗%∀
patients. We investigated patients receiving conventional GC therapy and patients treated with the modified ∗&∀
release hydrocortisone preparation Chronocort in comparison to healthy controls with intact diurnal ∗∋∀
secretion of cortisol.  ∗(∀
SUBJECTS AND METHODS ∗)∀
Subjects ∗∗∀
Alternative pathway androgen synthesis in subjects with CAH managed with conventional GC !++∀
therapy was quantified by analysis of 24-hour urinary steroid metabolite excretion in 55 adult subjects with !+!∀
21OHD, recruited from two specialist centers, Birmingham and Munich, and 60 sex- and age-matched !+#∀
controls, recruited from Birmingham. In all participating patients, the diagnosis of 21-hydroxylase !+∃∀
deficiency had previously been confirmed following genetic testing as part of their routine clinical care. !+%∀
Control subjects were healthy individuals without chronic disease aged 18-80 years. None were taking oral !+&∀
contraceptives, hormone replacement therapy other than corticosteroid replacement or other medications !+∋∀
known to alter steroid hormone synthesis and/or metabolism at the time of urine collection.  !+(∀
A summary of patient and control characteristics is provided in Table 1. The majority of the 21OHD group !+)∀
were managed with prednisolone (n=27; 49%; median daily dose 7.5 mg, range 5-15 mg) and the remainder !+∗∀
with either hydrocortisone (n=13; 24%; median daily dose 30 mg, range 20-37.5 mg) or dexamethasone !!+∀
(n=15; 27%; median daily dose 0.5 mg, range 0.25-1.00 mg). All patients with salt-wasting CAH and some !!!∀
∋∀
∀
with simple-virilizing CAH received additional mineralocorticoid replacement; daily fludrocortisone doses !!#∀
ranged between 100-300 µg. !!∃∀
The impact of the modified release hydrocortisone preparation Chronocort on alternative pathway !!%∀
synthesis was assessed in a subgroup consisting of 16 subjects with 21OHD. All were enrolled in an open-!!&∀
label phase 2 study at the National Institutes of Health Clinical Centre (clinical trials.gov #NCT01735617) !!∋∀
(14). Subjects were maintained on twice-daily Chronocort therapy for a period of six months with dose !!(∀
adjustment employed based on clinical symptoms and serum biochemistry. Median daily Chronocort dose !!)∀
at six months was 27.5 (range 15-40) mg. Urinary steroid metabolite excretion was measured at baseline, !!∗∀
at day four of Chronocort therapy and after six months of treatment. Three eight-hour urine samples were !#+∀
collected within each of these three 24 hour periods and were timed to reflect either night (23:00-07:00), !#!∀
morning (07:00-15:00) or evening (15:00-23:00) periods. Steroid excretion in the 8-hourly urine collection !##∀
was compared to that of 12 healthy control subjects (median age 32.9 years) who also provided three eight-!#∃∀
hour urine collections with similar timing to reflect night, morning or evening periods. All participants !#%∀
provided informed written consent. Ethical approval for the collection of baseline data was provided by !#&∀
South Birmingham Research Ethics Committee (REC) for healthy controls, and by West Midlands MREC !#∋∀
and the University Hospital Ethics Committee Munich for conventionally managed CAH patients. Phase 2 !#(∀
study approval for the Chronocort-treated CAH patients was provided by the Eunice Kennedy Shriver !#)∀
National Institute of Child Health and Human Development Institutional Review Board at the National !#∗∀
Institute of Health, USA. !∃+∀
Urinary steroid hormone analysis !∃!∀
Analysis of urinary excretion of steroid hormone metabolites was undertaken by quantitative gas !∃#∀
chromatography-mass spectrometry (GC-MS) in selected-ion-monitoring analysis mode as described !∃∃∀
previously (7). Suppl. Table 1 summarizes the steroid metabolites relevant to this study. !∃%∀
The 21-hydroxylase enzyme, CYP21A2, catalyzes the conversion of 17OHP to the cortisol !∃&∀
precursor 11-deoxycortisol. The metabolic impact of 21OHD was thus assessed through analysis of !∃∋∀
tetrahydro-11-deoxycortisol (THS), the metabolite of the CYP21A2 product 11-deoxycortisol, and the !∃(∀
(∀
∀
17OHP metabolites 17-hydroxypregnanolone (17HP) and pregnanetriol (PT) as well as pregnanetriolone !∃)∀
(PTONE). PTONE is the metabolite of 21-deoxycortisol, which is generated from 17OHP by CYP11B1 !∃∗∀
and only produced in appreciable amounts in the absence of 21-hydroxylase activity, i.e. in 21OHD.  !%+∀
Classic androgen pathway activity was measured by quantification of the major androgen !%!∀
metabolites androsterone (An) and etiocholanolone (Et). Activation of the alternative pathway to DHT was !%#∀
assessed through quantification of its signature metabolite 3α,5α-17HP. While androstenedione and !%∃∀
testosterone both feed into An and Et, the most potent androgen, DHT, is only represented in the 5α-reduced !%%∀
androgen metabolite An. Thus the Et pool is only enhanced by classic androgen pathway activity while the !%&∀
An pool increases with DHT synthesis via both the classic and alternative pathways. We therefore used the !%∋∀
ratio 3α5α17HP/An as an estimate of the proportional contribution of the alternative pathway to androgen !%(∀
synthesis. !%)∀
19-carbon androgens oxygenated at position C-11 have been shown to be produced by the adrenal !%∗∀
glands and 11-keto-testosterone and 11-keto-DHT have been shown to activate the androgen receptor (7, !&+∀
10). Therefore, we measured the concentration of the major metabolite of urinary 11-oxy-C19 steroid !&!∀
metabolites, 11β-hydroxyandrosterone (11β-OH-An).  !&#∀
Statistical analysis !&∃∀
Data are presented as median and interquartile range (IQR) unless otherwise stated. Analyses were !&%∀
undertaken using the non-parametric Mann-Whitney and Kruskal-Wallis with posthoc Dunn tests for !&&∀
unpaired analyses. Paired data was analyzed using the non-parametric Wilcoxon test with Bonferroni !&∋∀
correction applied for repeated analyses. Statistical analyses were undertaken using SPSS Statistics 21 !&(∀
(IBM) and p-values <0.05 considered significant. All p-values were two sided.  !&)∀
RESULTS !&∗∀
24-h steroid metabolite excretion in CAH patients receiving conventional glucocorticoid therapy  !∋+∀
)∀
∀
As expected, the excretion of the 17OHP metabolites 17HP and PT and the 21-deoxycortisol !∋!∀
metabolite PTONE, were significantly increased in CAH (p<0.001), indicative of impaired 21-hydroxylase !∋#∀
activity. Conversely, the product of 21-hydroxylase activity, the 11-deoxycortisol metabolite THS, was !∋∃∀
significantly lower (p<0.001) in subjects with CAH than in control subjects (Fig. 2A+B).  !∋%∀
The urinary excretion of the sum of the major androgen metabolites An and Et was significantly !∋&∀
lower in subjects with CAH managed with conventional GC therapy than in sex- and age-matched control !∋∋∀
subjects (Fig. 2C; p<0.001). Conversely, the signature metabolite of the alternative pathway to DHT !∋(∀
synthesis, 3α5α-17HP, was significantly increased in subjects with CAH (Fig. 2D; p<0.001). The ratio of !∋)∀
3α,5α-17HP to An was calculated in order to quantify the contribution of the alternative pathway to total !∋∗∀
synthesis of 5α-reduced androgens including DHT. This ratio was significantly increased in subjects with !(+∀
CAH while alternative pathway activity in the controls was negligible (p<0.001) (Fig. 2E). The excretion !(!∀
of the major metabolite of 11-oxygenated 19-carbon steroids, 11β-OH-An, appeared similar to that in !(#∀
controls, with broad inter-individual variability in excretion amounts (Fig. 2F).  The pattern of changes !(∃∀
remained similar when carrying out sex-specific sub group analyses (Suppl. Fig. 3), which also revealed !(%∀
higher excretion of the metabolites of 17OHP (Suppl. Fig. 3A) and classic and alternative pathway !(&∀
metabolites (Suppl. Fig. 3C,D,F) in male controls as compared to female controls, whereas no significant !(∋∀
difference was observed between male and female CAH patients. !((∀
Diurnal variation in steroid excretion in CAH patients receiving conventional glucocorticoid therapy  !()∀
Diurnal excretion analysis in urines collected in 8-hour intervals reflecting night (23:00-07:00h), !(∗∀
morning (7:00-15:00h) and evening (15:00-23:00h) showed a similar picture to the 24-h urine analysis !)+∀
when comparing CAH patients (n=16; four of whom were managed with hydrocortisone, seven with !)!∀
prednisolone and five dexamethasone) to control subjects (n=12), with lower classic pathway but higher !)#∀
excretion of the signature metabolite of the alternative pathway to DHT in CAH patients (Fig. 3).  !)∃∀
∗∀
∀
Healthy control subjects showed significant diurnal variability of the metabolites of 17OHP and !)%∀
the classic and alternative androgen pathways (Fig. 3), with lowest excretion during night time. By contrast, !)&∀
this diurnal excretion pattern was lost in CAH patients receiving conventional glucocorticoid therapy. !)∋∀
Differential impact of conventional glucocorticoid preparations on steroid excretion !)(∀
To assess the effect of distinct conventional GC therapies on androgen synthesis, we compared !))∀
urinary steroid metabolite excretion in CAH patients managed with hydrocortisone (n=13), prednisolone !)∗∀
(n=27), and dexamethasone (n=15), respectively; all had been on stable treatment for at least six months. !∗+∀
This revealed that hydrocortisone-treated CAH patients had significantly higher excretion of 17OHP !∗!∀
metabolites, the sum of the androgen metabolites An+Et and also the major adrenal androgen metabolite !∗#∀
11β-OH-An in comparison to dexamethasone-treated patients, with prednisolone-treated in an intermediate !∗∃∀
position (Suppl. Fig. 1). Similarly, hydrocortisone therapy appeared associated with the highest excretion !∗%∀
of the alternative pathway metabolite 3α,5α-17HP but this difference was not statistically significant due to !∗&∀
high inter-individual variability. !∗∋∀
Diurnal steroid excretion during modified release hydrocortisone treatment  !∗(∀
We assessed urinary steroid excretion in 16 patients with CAH at baseline, i.e. on conventional GC !∗)∀
treatment, and during treatment with modified release hydrocortisone, with diurnal urine collections in 8-!∗∗∀
hourly intervals. This was carried out on three occasions: at baseline when still receiving conventional GC #++∀
therapy, shortly after initiation of Chronocort treatment, day 4, and after six months of continuous treatment #+!∀
with Chronocort. #+#∀
 The analysis of the total 24-h urine excretion revealed a significant reduction in the combined #+∃∀
excretion of the markers of impaired 21-hydroxylase activity, the sum of 17α-hydroxyprogesterone #+%∀
metabolites 17HP, PT and the 21-deoxycortisol metabolite PTONE, both after four days and six months of #+&∀
Chronocort treatment (all p<0.05) (Fig. 4), with lower excretion amounts than observed in patients treated #+∋∀
with any other GC preparation (Fig. 5). Total classic pathway androgen metabolite excretion, An+Et, and #+(∀
excretion of the alternative androgen pathway metabolite 3α5α-17HP significantly decreased after #+)∀
!+∀
∀
Chronocort treatment to lower levels than observed with any other GC preparation (Fig. 4+5). The excretion #+∗∀
of 11β-OH-An also appeared to decrease albeit not significantly (Fig. 4). Attenuation of 11-oxygenated 19-#!+∀
carbon androgen synthesis in Chronocort-treated patients was at least similar to dexamethasone or #!!∀
prednisolone treatment and superior to the effects of hydrocortisone treatment (Fig. 5). Of note, 24-h #!#∀
urinary excretion of 11-hydroxy-etiocholanolone and 11-oxo-etiocholanolone, which are exclusive #!∃∀
glucocorticoid metabolites (15) and therefore reflective of the amount of exogenous cortisol, showed a #!%∀
higher excretion in patients treated with conventional hydrocortisone than in patients on Chronocort. #!&∀
The effect of six months of Chronocort therapy on the diurnal rhythm of urinary steroid excretion #!∋∀
in subjects with CAH is shown in Suppl. Fig. 2. There was less variability seen across the three 8-hour #!(∀
periods in the excretion of the metabolites of CYP21A2 following Chronocort than prior to its initiation. #!)∀
Notably, the early morning surge (night time period, 23:00-7:00h) in the activation of classic and alternative #!∗∀
androgen pathway synthesis appeared diminished following Chronocort therapy (Suppl. Fig. 2C-F). ##+∀
DISCUSSION ##!∀
In this study, employing 24-h urinary steroid metabolome profiling, we could show that alternative ###∀
pathway androgen synthesis contributes significantly to androgen excess in CAH patients receiving chronic ##∃∀
GC therapy, both via the 11-oxygenated 19-carbon androgen pathway and via DHT synthesis from 17OHP. ##%∀
In addition, we have identified the differential impact of conventional GC therapies and treatment with ##&∀
modified release hydrocortisone (Chronocort) on steroid excretion in CAH, including their effects on ##∋∀
alternative pathway androgen synthesis, namely the alternative “backdoor” pathway to DHT and the 11-##(∀
oxygenated C19 steroid pathway. ##)∀
Eleements of the alternative “backdoor” pathway to DHT were first described by Wilson, Auchus ##∗∀
and colleagues, reporting the synthesis of 5α-androstanediol from 17OHP, with 3α,5α-17HP as the #∃+∀
intermediate in the fetal testis of the tammar wallaby pouch young (5). They hypothesized that this pathway #∃!∀
could extend to the conversion of 5α-androstanediol to 5α-dihdyrotestosterone (DHT), thereby achieving #∃#∀
active androgen synthesis without the classic pathway intermediates DHEA, androstenedione and #∃∃∀
!!∀
∀
testosterone. This led Auchus to coin the term “backdoor pathway” for this alternative pathway to DHT #∃%∀
synthesis (3). They later showed that the final step to DHT can indeed take place in the gonads of the #∃&∀
brushtail possum, the tammar wallaby, and the short tail opossum (16-18). Arlt and colleagues were the #∃∋∀
first to suggest the relevance of the alternative pathway to DHT in humans, as an explanation for the #∃(∀
virilization of newborn girls affected by CAH, utilizing the example of CAH due to P450 oxidoreductase #∃)∀
deficiency, which results in disruption of the classic androgen pathway (4). Though that work focused on #∃∗∀
the role of the alternative pathway in prenatal life, they postulated that synthesis of DHT via the alternative #%+∀
pathway is likely to occur or increase, respectively, if there is an increase in either the availability of its #%!∀
substrate 17OHP or the activity of 5α-reductase type 1 activity, which catalyzes the first step of the #%#∀
alternative pathway. Both progesterone and 17OHP are efficient substrates for the 5α-reductase activity of #%∃∀
SRD5A1 (19) and both these steroids accumulate in CAH with impaired 21-hydroxylase activity. Ogata’s #%%∀
group showed increased urinary excretion of the alternative pathway intermediate 3α,5α-17HP in patients #%&∀
with CAH due to P450 oxidoreductase deficiency (20); P450 oxidoreductase serves as the electron donor #%∋∀
enzyme to 21-hydroxylase and therefore its disruption results in impaired 21-hydroxylase activity. #%(∀
Subsequently, Kamrath et al. demonstrated increased 3α,5α-17HP in newly diagnosed and hence untreated #%)∀
patients with CAH due to 21OHD aged 1 day to 25 years, noting the highest excretion amounts in the #%∗∀
neonatal period (6). In this study investigating the steroid metabolome in adult CAH patients on established #&+∀
GC therapy, we found that while classic androgen pathway activity was significantly reduced, there was #&!∀
significantly increased excretion of 3α,5α-17HP, indicating an increased relative contribution of alternative #&#∀
androgen pathway DHT synthesis to androgen excess in CAH also in adulthood and in patients receiving #&∃∀
regular GC treatment.  #&%∀
We also found increased excretion of 11β-OH-An, the major metabolite of 11-oxygenated 19-#&&∀
carbon androgens. Of note, Kamrath et al. also showed significantly increased excretion of 11β-OH-An in #&∋∀
untreated CAH patients. However, at the time, they considered 11β-OH-An a classic pathway metabolite, #&(∀
while in fact this steroid represents the major metabolite of 11β-hydroxy-androstenedione and other 11-#&)∀
!#∀
∀
oxygenated 19-carbon androgens (15), effectively the second alternative pathway to the synthesis of active #&∗∀
androgens. Its end products, 11-keto-testosterone and 11-keto-DHT, which have shown similar androgenic #∋+∀
activity to testosterone and DHT (7-10). In a very recent publication, serum metabolome profiling by #∋!∀
tandem mass spectrometry demonstrated 3-4 fold increased circulating concentrations of 11β-hydroxy-#∋#∀
androstenedione, 11-keto-androstenedione, 11β-hydroxy-testosterone, and 11-keto-testosterone in patients #∋∃∀
with 21OHD (21). However, this was done in a cross-sectional cohort of CAH patients with no detailed #∋%∀
data on GC therapy available. #∋&∀
In our study, conventional GC therapy appeared to control the activity of the alternative androgen #∋∋∀
synthesis pathways less efficiently than classic pathway synthesis. The latter we even found to be #∋(∀
significantly suppressed in CAH patients, below the levels observed in healthy sex- and age-matched #∋)∀
controls, indicative of relative GC over-treatment that is frequently observed in adult patients with CAH #∋∗∀
(22). Studying the diurnal variation of steroid excretion in our patients, we observed that the increased #(+∀
excretion of the alternative pathway metabolites 3α,5α-17HP and 11β-OH-An is most likely consequent to #(!∀
the early morning surge in ACTH, which is unopposed in CAH patients on conventional GC therapy. #(#∀
By contrast, we found that Chronocort, a modified release hydrocortisone preparation, exerted #(∃∀
much improved control of alternative pathway-mediated androgen excess. Chronocort has been shown to #(%∀
yield cortisol delivery mimicking physiological cortisol secretion (13), resulting in significant #(&∀
normalization of circulating 17OHP and androstenedione levels in a previously published phase 2 study in #(∋∀
CAH patients (14). This effect was almost more impressively visible when studying the urines of this cohort #((∀
of 16 patients in our study, with close to normalization of 17OHP metabolite excretion in Chronocort-#()∀
treated patients. Conventional GC treatment never normalizes 17OHP secretion and if present, this would #(∗∀
be considered an indicator of significant over-replacement. However, near normal diurnal provision of #)+∀
cortisol by Chronocort exerted superior control of 17OHP secretion and thereby also of both alternative #)!∀
androgen pathways driving androgen excess in CAH, which are both fed by the conversion of 17OHP, #)#∀
either to 11-oxygenated 19-carbons steroids or to 3α,5α-17HP and further downstream to DHT via the #)∃∀
!∃∀
∀
“backdoor pathway”. An alternative modified release formulation of hydrocortisone, Plenadren, has #)%∀
immediate and delayed release actions but is licensed for use in adrenal insufficiency, where it is taken first #)&∀
thing the morning as a once daily medication, (23)  and was not studied here. In the only paper to report #)∋∀
use of Plenadren in CAH, six patients with CAH were included in an open label trial of Plenadren where #)(∀
BMI, HbA1c and quality of life were measured but androgens were not reported.(24) #))∀
Importantly, in our study, the analysis of the exclusive cortisol metabolites 11β-hydroxy-#)∗∀
etiocholanolone and 11-oxo-etiocholanolone (15) clearly indicated a higher excretion in the patients on #∗+∀
conventional hydrocortisone treatment than in those treated with Chronocort, the modified release #∗!∀
hydrocortisone preparation. This means that the absolute amount of bioavailable cortisol was actually lower #∗#∀
in Chronocort-treated CAH patients, supporting the assumption that it was not the total amount of #∗∃∀
glucocorticoid but the improved diurnal delivery of cortisol by Chronocort, and therefore the better control #∗%∀
of the early morning ACTH and steroid surge, that results in the superior control of excess 17OHP and #∗&∀
androgen production. #∗∋∀
A limitation of our study was the fact the CAH patient groups receiving the three conventional GC #∗(∀
preparations, hydrocortisone, prednisolone and dexamethasone, were not matched for biochemical control #∗)∀
at baseline and were studied cross-sectionally and not during a controlled cross-over study. However, they #∗∗∀
were a cohort of considerable size recruited from two large specialist centers, which ensures a relative ∃++∀
homogenization of clinical presentation. An advantage of our study was the inclusion of adult patients only, ∃+!∀
which allowed us to dissect androgen production in detail. ∃+#∀
In conclusion, we have identified significant alternative androgen synthesis pathway activity in ∃+∃∀
adult patients with CAH on conventional GC therapy that persists despite suppression of classic pathway ∃+%∀
androgen production by relative glucocorticoid overtreatment. However, we found that the modified release ∃+&∀
hydrocortisone preparation Chronocort results in superior control of alternative pathway androgen ∃+∋∀
production, most likely by reducing the early morning surge in excess 17OHP, which in CAH represents ∃+(∀
the major substrate for both the alternative androgen pathway to DHT and the 11-oxygenated androgen ∃+)∀
pathway.  ∃+∗∀
!%∀
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FIGURE LEGENDS ∃∗∋∀
 ∃∗(∀
Fig. 1: Schematic overview of steroidogenesis. The graph depicts steroidogenesis including the classic ∃∗)∀
androgen synthesis pathway (shaded in dark grey) and the two alternative androgen synthesis pathways ∃∗∗∀
(shaded in light grey; top, 11-oxygenated 19-carbon steroids; bottom, alternative pathway to DHT). 3α,5α-%++∀
17HP is labelled by its alternative full name, 17-OH-allopregnanolone. %+!∀
 %+#∀
Fig. 2: 24-h urinary steroid excretion in 55 CAH patients and 60 healthy sex- and age-matched %+∃∀
controls. For explanation of steroid metabolite abbreviations see Table 1. Data are shown as µg/24 hours %+%∀
and presented as box-and-whisker plots to represent median, interquartile range (box), and 5
th
 and 95
th
 %+&∀
percentiles (whiskers). Urinary excretion of 3α5α-17HP available for 38 of the total CAH cohort. Analyses %+∋∀
were undertaken using the Mann-Whitney test. * p≤0.05, *** p≤0.001 for CAH vs. controls.  %+(∀
 %+)∀
Fig. 3: 8-hourly diurnal urinary steroid metabolite excretion in 16 subjects with CAH due to 21OHD %+∗∀
and 12 healthy controls. Data are shown for night (23:00-07:00; dark grey), morning (07:00-15:00; white) %!+∀
and evening (15:00-23:00; light grey) time periods. Excretion of the major androgen metabolites An+Et is %!!∀
shown for male subjects with CAH (n=8) and matched healthy controls (n=12). Box-and-whisker plots %!#∀
represent median, interquartile range (box), and 5
th
 and 95
th
 percentiles (whiskers). Comparisons were %!∃∀
drawn within CAH and control groups with analyses undertaken using the Friedman test, which was applied %!%∀
to the CAH subjects and the control subjects separately. * p≤0.05 for comparison of steroid excretion during %!&∀
different 8-h periods. %!∋∀
 %!(∀
Fig. 4: Effect of Chronocort treatment on 24-hour urinary steroid metabolite excretion in subjects %!)∀
with CAH due to 21OHD. Results are shown for subjects with CAH at baseline on conventional GC %!∗∀
therapy prior to commencing Chronocort (BL; n=16), at day 4 of Chronocort treatment (D4; n=16) and %#+∀
after six months of Chronocort treatment (M6; n=15). Box-and-whisker plots represent median, %#!∀
#+∀
∀
interquartile range (box), and 5
th
 and 95
th
 percentiles (whiskers). Analyses were undertaken using repeated %##∀
Wilcoxon tests with Bonferroni correction to compare between matched CAH subjects. * p≤0.05. %#∃∀
 %#%∀
Fig. 5: Urinary steroid excretion in 60 healthy controls and CAH patients treated with Chronocort %#&∀
(n=16), conventional immediate release hydrocortisone (n=13), prednisolone (n=27) or %#∋∀
dexamethasone (n=15). Urinary excretion of 3α5α-17HP available for 54 of the total CAH cohort; 16 on %#(∀
Chronocort, 11 on conventional hydrocortisone, 21 on prednisolone and 6 on dexamethasone. %#)∀
Glucocorticoid treatment was stable for at least six months at the time of 24-h urine collection. Box-and-%#∗∀
whisker plots represent median, interquartile range (box), and 5
th
 and 95
th
 percentiles (whiskers). Analyses %∃+∀
were undertaken using the Kruskal-Wallis test with post-hoc Dunn. * p≤0.05, *** p≤0.001. %∃!∀
  %∃#∀
#!∀
∀
Table 1:  Demographic data for participants with CAH managed with either conventional glucocorticoid %∃∃∀
(GC) treatment or Chronocort and healthy matched control subjects. Data for age are shown as median %∃%∀
(range). For Chronocort-treated patients their conventional GC medication prior to commencing %∃&∀
Chronocort therapy is shown.  %∃∋∀
  CAH 
patients on 
conventional 
GC therapy 
Control 
cohort 
 
Chronocort-
treated 
CAH 
patients 
Control 
cohort 
Number 
 
N=55 N=60 N=16 n=12 
Sex Male : Female n:n 28 : 27 32 : 28 8 : 8 12 : 0 
Age (years)  31 (19-49) 26 (20-48) 24 (18-60) 28.5 (22-60) 
CAH 
phenotype
 
Salt-wasting (%) 41 (74.5)
 
- 12 (75) - 
 Simple virilizing (%) 14 (25.5) - 4 (25) - 
Glucocorticoid 
preparation 
Hydrocortisone n (%) 13 (24) - 3 (19) - 
Prednisolone n (%) 27 (49) - 8 (50)* - 
 Dexamethasone n (%) 15 (27) - 5 (31) - 
 %∃(∀
* One patient received a combined hydrocortisone and prednisolone preparation prior to commencing %∃)∀
Chronocort therapy and has been included in the prednisolone group%∃∗∀
##∀
∀
Fig. 1: Schematic overview of steroidogenesis.  
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Fig. 2: 24-h urinary steroid excretion in 55 CAH patients and 60 healthy sex- and age-matched 
controls.  
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Fig. 3: 8-hourly diurnal urinary steroid metabolite excretion in 16 subjects with CAH due to 21OHD 
and 12 healthy controls. 
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Fig. 4: Effect of Chronocort treatment on 24-hour urinary steroid metabolite excretion in 
16subjects with CAH due to 21OHD.   
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Fig. 5: Urinary steroid excretion in 60 healthy controls and CAH patients treated with Chronocort 
(n=16), conventional immediate release hydrocortisone (n=13), prednisolone (n=27) or 
dexamethasone (n=15). 
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